AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Tian, Yuantong ^a,c   Zhao, Lijing ^a   Zhang, Haitao ^b   Liu, Xichun ^b   Zhao, Lijuan ^a   Zhao, Xuejian ^a   Li, Yi ^a   Li, Jing ^a  

^a JILIN UNIVERSITY   (China)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

AKR1C3; Biomarker; Gleason score; Prostate cancer; PSA

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER GRADING; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY; XENOGRAFT;

3-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; DISEASE PROGRESSION; HETEROGRAFTS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84895141227     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-42     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989, 321(7):419-424. 10.1056/NEJM198908173210702, 2503724.
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339(15):1036-1042. 10.1056/NEJM199810083391504, 9761805.
4. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002, 52(3):154-179. 10.3322/canjclin.52.3.154, 12018929.
5. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010, 21(5):315-324. 10.1016/j.tem.2010.01.002, 2862880, 20138542.
6. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Ceraline J. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 2008, 617:529-534. 10.1007/978-0-387-69080-3_53, 18497078.
7. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH, Sheng S. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 2006, 98(6):1408-1423. 10.1002/jcb.20927, 16619263.
8. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schroder FH, de Jong FH. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010, 70(3):1256-1264. 10.1158/0008-5472.CAN-09-2092, 20086173.
9. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 2011, 17(7-8):657-664. 3146625, 21365123.
10. Byrns MC, Mindnich R, Duan L, Penning TM. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J Steroid Biochem Mol Biol 2012, 130(1-2):7-15. 3319280, 22265960.
11. Dozmorov MG, Azzarello JT, Wren JD, Fung KM, Yang Q, Davis JS, Hurst RE, Culkin DJ, Penning TM, Lin HK. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer 2010, 10:672. 10.1186/1471-2407-10-672, 3013086, 21134280.
12. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006, 13(1):169-180. 10.1677/erc.1.01048, 16601286.
13. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Yamada S, Arai Y, Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005, 12(1):101-107. 10.1677/erc.1.00914, 15788642.
14. Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci 2013, 68(1):56-61. 10.1093/gerona/gls135, 3598363, 22562961.
15. Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998, 19(4):365-396.
16. Azzarello J, Fung KM, Lin HK. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem 2008, 56(9):853-861. 10.1369/jhc.2008.951384, 2516960, 18574251.
17. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008, 61(4):448-454. 10.1136/jcp.2007.050906, 17720776.
18. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002, 9(1):61-73. 10.1677/erc.0.0090061, 11914183.
19. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011, 108(33):13728-13733. 10.1073/pnas.1107898108, 3158152, 21795608.
20. Wang S, Yang Q, Fung KM, Lin HK. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol 2008, 289(1-2):60-66.
21. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007, 97(12):1690-1695. 10.1038/sj.bjc.6604054, 2360284, 17971772.
22. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59(23):5975-5979.
23. Dabir PD, Ottosen P, Hoyer S, Hamilton-Dutoit S. Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol 2012, 7:81. 10.1186/1746-1596-7-81, 3434074, 22800084.
24. Yin M, Dhir R, Parwani AV. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol 2007, 2:41. 10.1186/1746-1596-2-41, 2174437, 17963516.
25. McGuire BB, Helfand BT, Loeb S, Hu Q, O'Brien D, Cooper P, Yang X, Catalona WJ. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. BJU Int 2012, 109(12):1764-1769. 10.1111/j.1464-410X.2011.10628.x, 22017732.
26. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008, 112(6):1247-1253. 10.1002/cncr.23304, 18293426.
27. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol 2012, 65(3):620-627.
28. Mulholland DJ. PSA-negative/low prostate cancer cells: the true villains of CRPC?. Asian J Androl 2012, 14(5):663-664. 10.1038/aja.2012.69, 3734974, 22820854.